294 related articles for article (PubMed ID: 34845730)
1. Host factors and vaccine efficacy: Implications for COVID-19 vaccines.
Falahi S; Kenarkoohi A
J Med Virol; 2022 Apr; 94(4):1330-1335. PubMed ID: 34845730
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccine breakthrough infections.
Gupta RK; Topol EJ
Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
[TBL] [Abstract][Full Text] [Related]
3. Metabolic disorders, COVID-19 and vaccine-breakthrough infections.
Stefan N
Nat Rev Endocrinol; 2022 Feb; 18(2):75-76. PubMed ID: 34873287
[TBL] [Abstract][Full Text] [Related]
4. A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques.
O'Connor MA; Erasmus JH; Randall S; Archer J; Lewis TB; Brown B; Fredericks M; Groenier S; Iwayama N; Ahrens C; Garrison W; Wangari S; Guerriero KA; Fuller DH
Front Immunol; 2021; 12():800723. PubMed ID: 34992610
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
[TBL] [Abstract][Full Text] [Related]
6. Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Dec; 385(25):e100. PubMed ID: 34910868
[No Abstract] [Full Text] [Related]
7. COVID vaccine makers brace for a variant worse than Delta.
Waltz E
Nature; 2021 Oct; 598(7882):552-553. PubMed ID: 34671153
[No Abstract] [Full Text] [Related]
8. Audio Interview: Waning Immunity against SARS-CoV-2.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Dec; 385(24):e99. PubMed ID: 34879456
[No Abstract] [Full Text] [Related]
9. Evolution of SARS-CoV-2: A prediction on the lineages and vaccine effectiveness.
Priyanka ; Choudhary OP; Singh I
Travel Med Infect Dis; 2021; 40():101983. PubMed ID: 33548551
[No Abstract] [Full Text] [Related]
10. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.
Kozlovskaya LI; Piniaeva AN; Ignatyev GM; Gordeychuk IV; Volok VP; Rogova YV; Shishova AA; Kovpak AA; Ivin YY; Antonova LP; Mefyod KM; Prokosheva LS; Sibirkina AS; Tarasova YY; Bayurova EO; Gancharova OS; Illarionova VV; Glukhov GS; Sokolova OS; Shaitan KV; Moysenovich AM; Gulyaev SA; Gulyaeva TV; Moroz AV; Gmyl LV; Ipatova EG; Kirpichnikov MP; Egorov AM; Siniugina AA; Ishmukhametov AA
Emerg Microbes Infect; 2021 Dec; 10(1):1790-1806. PubMed ID: 34427172
[TBL] [Abstract][Full Text] [Related]
11. Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern.
Martín-Galiano AJ; Díez-Fuertes F; McConnell MJ; López D
Front Immunol; 2021; 12():732693. PubMed ID: 34899692
[TBL] [Abstract][Full Text] [Related]
12. Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines-Correlates of Immunogenicity Parameters with Protection.
Vajo Z
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215791
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
[No Abstract] [Full Text] [Related]
14. COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.
He Q; Mao Q; Zhang J; Bian L; Gao F; Wang J; Xu M; Liang Z
Front Immunol; 2021; 12():669339. PubMed ID: 33912196
[TBL] [Abstract][Full Text] [Related]
15. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
[No Abstract] [Full Text] [Related]
16. Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
N Engl J Med; 2022 Feb; 386(6):599-601. PubMed ID: 35030645
[No Abstract] [Full Text] [Related]
17. Scientists see a 'really, really tough winter' with Omicron.
Kupferschmidt K
Science; 2021 Dec; 374(6574):1421-1422. PubMed ID: 34914506
[No Abstract] [Full Text] [Related]
18. The long road.
Cohen J
Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
[No Abstract] [Full Text] [Related]
19. COVID-19 vaccinations: The unknowns, challenges, and hopes.
Mohamed K; Rzymski P; Islam MS; Makuku R; Mushtaq A; Khan A; Ivanovska M; Makka SA; Hashem F; Marquez L; Cseprekal O; Filgueiras IS; Fonseca DLM; Mickael E; Ling I; Arero AG; Cuschieri S; Minakova K; Rodríguez-Román E; Abarikwu SO; Faten AB; Grancini G; Cabral-Marques O; Rezaei N
J Med Virol; 2022 Apr; 94(4):1336-1349. PubMed ID: 34845731
[TBL] [Abstract][Full Text] [Related]
20. Oldest Adults Need 2 mRNA Vaccine Doses to Neutralize SARS-CoV-2.
Abbasi J
JAMA; 2021 Aug; 326(6):473. PubMed ID: 34374737
[No Abstract] [Full Text] [Related]
[Next] [New Search]
